Another significant step towards the success of ICVAX® HONG KONG SAR – Media OutReach Newswire – 27 May 2026 – Immuno Cure Group (“Immuno Cure“), headquartered at Hong Kong Science Park, is pleased to announce the inauguration of the research...

HONG KONG SAR – Media OutReach Newswire – 26 January 2026 – Immuno Cure BioTech (“Immuno Cure“) is pleased to announce today the initiation of a Phase I clinical study of ICVAX, a therapeutic DNA vaccine for HIV, in collaboration...

“a prominent recognition attracting RMB 60M investment EOI” HONG KONG SAR – Media OutReach Newswire – 6 October 2025 – Immuno Cure BioTech (“Immuno Cure“) is delighted to announce victory at the National Final of the 1st GBA Entrepreneurship Competition...